Bausch + Lomb has acquired an exclusive global license to a technology that may lead to a faster, more effective, and longer lasting treatment for ocular redness. The technology employs a uniquely formulated low dose of brimonidine. Licensed from Eye Therapies, LLC, the technology was developed in collaboration with Ora Inc. One of the most common ophthalmologic conditions, ocular redness, or hyperemia, can be triggered by contact lens wear, dry eye, ocular allergies, lifestyle and environmental factors, and medication side effects. Read more.
No comments:
Post a Comment